US2004162327A1PendingUtilityA1

Crystalline form of telmisartan sodium

Assignee: BOEHRINGER INGELHEIM PHARMAPriority: Oct 31, 2001Filed: Feb 12, 2004Published: Aug 19, 2004
Est. expiryOct 31, 2021(expired)· nominal 20-yr term from priority
C07D 235/20
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a crystalline sodium salt of 4′-[2-n-propyl-4-methyl-6-(1-methyl-benzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), processes for preparing it and the use thereof for preparing a pharmaceutical composition.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A compound of formula 2  
       
         
           
           
               
               
           
         
       
       wherein H—X denotes an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, toluenesulphonic acid and methanesulphonic acid.  
     
     
         2 . The compound of formula 2 according to  claim 1 , wherein H—X denotes hydrogen chloride.  
     
     
         3 . A compound according to  claim 1  or  claim 2 , in crystalline form.

Join the waitlist — get patent alerts

Track US2004162327A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.